Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06662760

Clinical Trial of TQB3002 in Patients With Advanced Cancers

Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2025-11-25

150

Participants Needed

11

Research Sites

94 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers

CONDITIONS

Official Title

Clinical Trial of TQB3002 in Patients With Advanced Cancers

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntarily agree to join the study, sign consent, and comply with study requirements
  • Age 18 years or older
  • ECOG performance status of 0 or 1
  • Expected survival longer than 3 months
  • Histologically or cytologically confirmed advanced cancer
  • Have failed standard therapy or lack effective treatment options
  • Major organs functioning well
  • Agree to use contraception during the study and for 6 months after if of childbearing potential
Not Eligible

You will not qualify if you...

  • Presence of other cancers within 5 years before first dose
  • Any unresolved toxicity above mild (CTCAE Grade 1) from previous anti-tumor therapy
  • Major surgery, biopsy, or significant injury within 4 weeks before first dose
  • Long-term unhealed wounds or fractures
  • Stroke, deep vein thrombosis, or pulmonary embolism within 6 months before first dose
  • Swallowing problems, active gastrointestinal diseases, or prior major stomach surgery
  • History of psychotropic drug abuse or mental disorder
  • Any severe or uncontrolled disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 11 locations

1

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China, 510180

Actively Recruiting

2

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

Shenzhen, Guangdong, China, 518117

Not Yet Recruiting

3

Henan Cancer Hospital

Zhengzhou, Henan, China, 450003

Not Yet Recruiting

4

Jiangsu Province Hospital

Nanjing, Jiangsu, China, 210029

Not Yet Recruiting

5

The First Affiliated Hospital Of Nanchang University

Nanchang, Jiangxi, China, 330038

Not Yet Recruiting

6

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China, 200000

Not Yet Recruiting

7

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China, 710004

Not Yet Recruiting

8

The First Affiliated Hospital of Xi'an Jiao Tong University

Xi’an, Shanxi, China, 710061

Not Yet Recruiting

9

Sichuan Cancer Hospital

Chengdu, Sichuan, China, 610040

Not Yet Recruiting

10

Mianyang Central Hospital

Mianyang, Sichuan, China, 621099

Not Yet Recruiting

11

Yunnan Cancer Hospital

Kunming, Yunnan, China, 650118

Not Yet Recruiting

Loading map...

Research Team

Q

Qing Zhou, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here